Depatuxizumab MMAE

BPS Bioscience

Depatuxizumab MMAE

23

Research Use Only

Monoclonal

≥90%

EGFR

epidermal growth factor receptor

ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS, PIG61, mENA, epidermal growth factor receptor, EGFR vIII, avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, cell growth inhibiting protein 40, cell proliferation-inducing protein 61, epidermal growth factor receptor tyrosine kinase domain, erb-b2 receptor tyrosine kinase 1, proto-oncogene c-ErbB-1, receptor tyrosine-protein kinase erbB-1

Epidermal growth factor receptor

Depatuxizumab MMAE is an antibody-drug conjugate (ADC) comprising an anti EGFR monoclonal antibody (Depatuxizumab) and the cytotoxic agent Monomethyl auristatin E (MMAE). Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR1.

-80°C

41116161

Human